STOCK TITAN

Teva- Pharmaceutical Industries Ltd. - TEVA STOCK NEWS

Welcome to our dedicated news page for Teva- Pharmaceutical Industries Ltd. (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva- Pharmaceutical Industries Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Teva- Pharmaceutical Industries Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Teva- Pharmaceutical Industries Ltd.'s position in the market.

Rhea-AI Summary
Data from the UNITE study presented at the World Congress of Neurology shows that AJOVY® (fremanezumab) reduces migraine attacks and depression symptoms in migraine patients with major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
clinical trial
-
Rhea-AI Summary
Teva achieves 0.005% incident rate with FourKites' global carrier visibility solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceutical Industries to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Sanofi and Teva Pharmaceuticals announce a collaboration to co-develop and co-commercialize asset TEV '574, a therapy for ulcerative colitis and Crohn's disease. Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Initial program results expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
Rhea-AI Summary
Sanofi and Teva Pharmaceuticals announce a collaboration to co-develop and co-commercialize asset TEV '574, a therapy for ulcerative colitis and Crohn's disease. Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Initial program results expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceutical Industries announces leadership changes. Sven Dethlefs to leave on Nov 17, 2023. Chris Fox appointed as head of Teva's U.S. Commercial Business. Fox brings 30 years of healthcare industry experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
Rhea-AI Summary
Teva Pharmaceutical Industries CEO to present at Morgan Stanley Global Healthcare Conference on September 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
conferences
-
Rhea-AI Summary
Teva Pharmaceuticals announces 16 data presentations at Psych Congress, highlighting AUSTEDO, UZEDY, TV-44749, and AJOVY. AUSTEDO XR and UZEDY received FDA approval. Positive potential for patients with TD, HD, and schizophrenia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
-
Rhea-AI Summary
Teva Pharmaceuticals reaches deferred prosecution agreement with the U.S. Department of Justice to settle price-fixing charges. Teva will pay a fine of $225 million over five years, donate $50 million worth of products, and divest one generic product. Former employee involved in bidding agreement. Teva emphasizes commitment to compliance and delivering quality medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.58%
Tags
earnings
Teva- Pharmaceutical Industries Ltd.

NYSE:TEVA

TEVA Rankings

TEVA Stock Data

15.82B
1.12B
53.42%
0.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O B 3190

About TEVA

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.